ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2701

Increased Frequency of Regulatory CD19+CD24high Cd38high B Cells in Patients with Ankylosing Spondylitis (AS)

M. Belén Bautista-Caro1, Eugenio De Miguel1, Diana Peiteado1, Chamaida Plasencia-Rodriguez1, Alejandro Villalba1, Amaya Puig-Kröger2, Paloma Sanchez-Mateos3, Emilio Martín-Mola1 and Maria Eugenia Miranda-Carus1, 1Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, 2Immuno-oncology, Hospital Gregorio Marañon, Madrid, Spain, 3Immunology, Hospital Gregorio Marañon, Madrid, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: ankylosing spondylitis (AS) and regulatory cells, B cells

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: CD19+CD24highCD38high B cells have been described to have a regulatory capacity and their frequency is altered in the peripheral blood of patients with various autoimmune diseases. The pathogenesis of AS is not well understood, and evidence suggesting the implication of either autoinflammatory or autoimmune mechanisms has been reported. In addition, increased frequencies of circulating B cells bearing a regulatory phenotype has recently been described in spondyloartrhitis (1). Therfore our objective was to study the frequency of circulating CD19+CD24high CD38high B cells (Breg) in patients with Ankylosing Spondylitis (AS), and test the regulatory capacity of this B cell subset.

Methods: Peripheral blood was drawn from AS patients naïve for TNF blockers (AS/nb) (n=41) and healthy controls (HC) (n=41), that were matched with patients for age and gender. After isolation by Ficoll-Hypaque gradient, PBMCs were stained with antibodies to CD3, CD4, CD19, CD24, and CD38, and examined by flow cytometry. For functional studies, total CD19+ B cells were isolated from PBMCs of 3 HC by magnetical sorting. Breg-depleted CD19+ B cells were obtained after total CD19+ B cells were depleted of CD19+CD24highCD38high B cells by cytometry in a FacsVantage sorter (Beckton Dickinson). Total CD19+ B cells or Breg-depleted CD19+ B cells were established in culture and stimulated through their BCR. Secretion of IFNγ was determined by ELISA in culture supernatants.

Results: When compared with healthy controls, AS/nb patients demonstrated a significantly increased frequency of CD19+CD24highCD38high B cells (Breg). The frequency of circulating Breg was increased not only in AS/nb patients with high or very high disease activity (ASDAS-CRP) >2.1 but also in AS patients with low activity or no activity (ASDAS-CRP< 2.1). The frequency of circulating Breg cells did not correlate significantly with ASDAS-CRP, ASDAS-ESR, BASDAI, CRP or ESR values. Functional in vitro studies showed that the secretion of IFNγ was significantly higher in Breg-depleted CD19+ as compared with total CD19+ B cells, indicating that Breg have the capacity to downmodulate B cell pro-inflammatory cytokine secretion.

Conclusion: An increased frequency of circulating CD19+CD24highCD38high B cells is observed in AS/nb patients, that is not related with disease activity. Functional in vitro studies confirmed that CD19+CD24highCD38high B cells are able to downmodulate B cell pro-inflammatory cytokine secretion. References: (1) Cantaert T, Doorenspleet ME, Francosalinas G, Paramarta JE, Klarenbeek PL, Tiersma Y, van der Loos CM, De Vries N, Tak PP, Baeten DL. Increased numbers of CD5+ B lymphocytes with a regulatory phenotype in spondylarthritis. Arthritis Rheum. 2012;64 :1859-68.


Disclosure: M. B. Bautista-Caro, Roche Pharmaceuticals, 2; E. De Miguel, None; D. Peiteado, None; C. Plasencia-Rodriguez, None; A. Villalba, None; A. Puig-Kröger, None; P. Sanchez-Mateos, None; E. Martín-Mola, Roche Pharmaceuticals, 2; M. E. Miranda-Carus, Roche Pharmaceuticals, 2.

To cite this abstract in AMA style:

Bautista-Caro MB, De Miguel E, Peiteado D, Plasencia-Rodriguez C, Villalba A, Puig-Kröger A, Sanchez-Mateos P, Martín-Mola E, Miranda-Carus ME. Increased Frequency of Regulatory CD19+CD24high Cd38high B Cells in Patients with Ankylosing Spondylitis (AS) [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/increased-frequency-of-regulatory-cd19cd24high-cd38high-b-cells-in-patients-with-ankylosing-spondylitis-as/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-frequency-of-regulatory-cd19cd24high-cd38high-b-cells-in-patients-with-ankylosing-spondylitis-as/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology